1. Home
  2. > Healthcare
  3. > Medical Device
  4. > In Vitro Diagnostics Market Trends
Hemostasis Diagnostic Devices And Equipment Global Market Report 2022

Hemostasis Diagnostic Devices And Equipment Global Market Report 2022

  • May 2022
  • ID: 6277239
  • Format: PDF
  • The Business Research Company


Table of Contents

Major players in the hemostasis diagnostic devices and equipment market are C.R. Bard, Baxter International Inc, Pfizer Inc, Johnson & Johnson, Abbott Laboratories, Beckman Coulter Inc, Becton, Dickinson and Company, Chrono-Log Corporation, CSL Behring LLC, and F. Hoffmann-La Roche Ltd.

The global hemostasis diagnostic devices and equipment market is expected to grow from $4.1 billion in 2021 to $4.81 billion in 2022 at a compound annual growth rate (CAGR) of 17.4%. The market is expected to grow to $8.57 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%.

The hemostasis diagnostic devices and equipment market consists of sales of hemostasis diagnostic devices.Hemostasis is a process of slowing and stopping the blood flow to initiate wound healing after a vascular injury.

Hemostasis is the first step of healing a wound, it happens in three main stages, blood coagulation, platelet plug formation, and lastly vasoconstriction.Three types of devices help speed up the hemostasis process, vascular closure devices (VCD), compression devices, and there are bandages coated with agents which will speed the clotting process.

With the help of hemostasis diagnostic devices, we can predict the cause of bleeding during surgery by identifying any hemostatic defects which patients may have.

The main products of hemostasis diagnostic devices and equipment are analyzers, coagulation instruments, other hemostasis instruments, and reagents and kits.A hemostasis diagnostic analyzer is a tool utilized to predict the cause of bleeding during surgery by identifying any hemostatic defects.

The hemostasis diagnostic devices and equipment are automated, semi-automated, and manual that is used by hospitals, clinics, independent diagnostic, laboratories, and others.

North America was the largest region in the hemostasis diagnostic devices and equipment market in 2021.Asia Pacific was the second-largest region in the hemostasis diagnostic devices and equipment market.

The regions covered in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The increased likelihood of older people being diagnosed with a disease is driving the number of surgeries such as cardiovascular diseases (CVD), using hemostasis devices.Due to the higher incidence of diseases with advancing age, there is an increase in the number of surgeries in elderly patients nowadays.

These hemostasis devices are very efficient in speeding up the natural process of clotting in the blood and can monitor anticoagulation and transfusion therapy guidance in any surgery.

According to the American Heart Association report, Americans older than 80 have a high risk of devolving a cardiovascular disease (CVD), around 83% of men and 87.1% of females will be suffering from any form of CVD, therefore, to improve the comfort of the patient and the success rate of surgeries as a result hemostasis device has been implemented widely.

The use of hemostasis devices in hospitals or clinics requires a very lengthy approval procedure which is restraining the market.Before hemostasis devices can enter the market for commercial use they have to clear the regulations set by the Code of Federal Regulations (title 21).

The process of approval consists firstly identification of the device, secondly classification of the device and finally, the date of the pre-market approval (PMA) or the notice of completion of prescription drug plan (PDP) is required.It is a very long and time-consuming approval process that discourages new entrants from entering this market.

For example, Cardiva medical Inc. had to wait for a processing period of four months before they received approval to change the existing equipment with a newer and modern one.

The emergence of new and improved technology in the hemostasis diagnostic device and equipment market.To improve the quality and success rate of operations, new and improved technology such as the collagen vascular hemostasis devices have been implemented.

Collagen is the main structural protein found in skin and other connective tissues.It is widely used in purified form for cosmetic surgical treatments and has now emerged in the hemostasis diagnostic devices market.

A patient can face immobility right after a femoral surgery leading to increased discomfort, as a result, collagen-based closure devices have been implemented.According to a study conducted by the American Journal of Neuroradiology which they surveyed 698 Angio-Seal closures, using the Angio seal reduced the average time before mobilization by close to 15 minutes with no major complications.

Angio seal is a type of collagen hemostasis device which reduces the average time of hemostasis and betters the mobilization of the patient.

In 2021, Baxter International Inc., a leading global medical products company, has announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc for up to $60.8 million, as well as $25 million paid upfront. This acquisition helps the transaction reinforces Baxter’s strategy of acquiring products and technologies that both complement and augment the company’s leading portfolio. CryoLife, Inc. is one of the world’s leading contemporary medical device companies.

The countries covered in the hemostasis diagnostic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Hemostasis Diagnostics Industry

  • $ 4950
  • October 2022
  • 173 pages

Abstract: What’s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-pee ...

  • World
  • China
  • Coagulation Diagnostic
  • Industry analysis


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on